# Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis

Source: https://onco.cc/trials/nct06315010/  
OnCo record `nct06315010` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of repotrectinib in lung cancer, run by MedSIR, now recruiting.

## Summary

Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis is a phase 2, interventional study registered as NCT06315010 by MedSIR, with a registry enrolment figure of 20 participants, started 2025-06-27 and due to reach its primary completion in 2027-03. Interventions recorded: Repotrectinib. Conditions listed: NSCLC; Brain Metastases; ROS1 Gene Rearrangement. Primary outcome: Intracranial Objective Response Rate (IC-ORR). Lung eligibility wording from the registry: "Histologically documented NSCLC". Sites: Austria, Germany, Spain. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: REPOSE
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06315010
- Phase: 2
- Setting: A Phase II Study Assessing Safety and Efficacy of Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis (The REPOSE Study)
- Sponsor: MedSIR
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06315010: https://clinicaltrials.gov/study/NCT06315010

## Connected records

- cancers: [ROS1-positive non-small-cell lung cancer](https://onco.cc/cancers/ros1-positive-nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Repotrectinib](https://onco.cc/drugs/repotrectinib/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06315010.json